{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Stable Disease (SD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Progression of Disease (POD)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"groups":[{"description":"This study will employ a Simon optimal two-stage design. Patients will receive lenalidomide 25 mg daily for days 1-21 of each 28 day cycle. Rituximab 375 mg/m2 will be given weekly for 4 weeks beginning 1 week after the start of lenalidomide therapy (weeks 2-5), and then once 8 weeks later (week 13). Patients with stable disease or better after 4 cycles (week 16, in the absence of delays for toxicity) will be able to continue on therapy on the same lenalidomide schedule and with rituximab 375 mg/m2 given once every 8 weeks.","id":"OG000","title":"Lenalidomide and Rituximab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Final Response Rate After 4 Courses of Treatment","type":"PRIMARY","unitOfMeasure":"participants"}